NVO Novo Nordisk A/S
Company Analysis
Latest News
🔴 Novo Nordisk is trading 3.08% down today after Citi cited slowing GLP-1 prescriptions
Novo Nordisk is trading at $46.05, down -3.08%, after Citi reiterated its sell rating, citing slowing GLP-1 prescriptions. - Citi also cited a 265 Danish...
Novo Nordisk Announces Strategic Collaboration to Build Quantum Chip Facility
Novo Nordisk and the Novo Nordisk Foundation established Quantum Foundry Copenhagen in Denmark. This facility will manufacture quantum chips. The initiative...
🟢 Novo Nordisk is trading 3.04% up today after Wegovy pill launch in Germany
Novo Nordisk is trading at $46.49, up 3.04% following the September 1, 2026 launch of the Wegovy pill in Germany. - Germany is the first EU market for the...
Novo Nordisk Debuts Wegovy Pill in Germany, Marking First EU Launch
Novo Nordisk will launch the tablet version of its Wegovy weight-loss drug in Germany on September 1, 2026. This release marks the first oral semaglutide...
Novo Nordisk Begins New Obesity Drug Trial in Asia
Novo Nordisk received approval to begin a Phase 3 clinical trial in South Korea for its next-generation obesity drug candidate, ZenaGamtide (amycretin). The...
🔴 Novo Nordisk is trading 3.1% down today after Deutsche Bank downgraded shares to sell
Novo Nordisk is trading 3.09% down at $45.73 after Deutsche Bank downgraded the shares to sell and cut its price target by 9%, citing heightened concerns after...
Novo Nordisk Advances Oral Wegovy in China, Targeting World's Second-Largest Market
China’s National Medical Products Administration accepted Novo Nordisk’s marketing application for the oral version of Wegovy. This marks a critical step...
🟢 Novo Nordisk is trading 3.17% up in after-hours trading as UK Foundayo launch intensifies oral obesity-drug competition
Novo Nordisk is trading 3.17% up at $48.68 after-hours, as Eli Lilly’s Foundayo became available in the UK, intensifying oral obesity-drug competition with...
🔴 Novo Nordisk is trading 3.07% down today after Eli Lilly's UK Foundayo launch
Novo Nordisk is trading 3.07% down at $47.16 after Eli Lilly launched its competing Foundayo oral weight-loss treatment in the UK on August 24, intensifying...
🟢 Novo Nordisk is trading 3% up today after JPMorgan raised 2026 sales forecasts
Novo Nordisk is trading $48.33 (+3.01%) after JPMorgan raised its 2026 sales forecast and price target. • Wegovy forecasts increased 7% to 82 billion Danish...
Novo Nordisk rises, following JPMorgan target hikes on Wegovy sales growth
Novo Nordisk shares rose as much as 2.2% on August 25, 2026. JPMorgan increased its 2026 sales expectations and stock price target for the company. Analysts...
Farallon Capital more than triples its stake in Novo Nordisk
Farallon Capital Management significantly increased its investment in pharmaceutical company Novo Nordisk, boosting its holdings by nearly 235% to 2.62 million...
Novo Nordisk tests low-dose oral Wegovy, targeting broader obesity market access
Novo Nordisk launched a Phase 3 clinical trial for an oral version of its obesity treatment, Wegovy. The study evaluates lower doses of oral semaglutide to...
Novo Nordisk CEO Confident in Diverse Obesity Drug Market, Downplays "Winner-Take-All" Scenario
Novo Nordisk's CEO, Mike Doustdar, stated that he does not foresee a "winner-take-all" market for obesity drugs. In an interview with Reuters, he compared the...
Novo Nordisk Downgraded to 'Hold' by Berenberg Amid Competitive Pressure
Berenberg Bank downgraded Novo Nordisk (NVO) from "buy" to "hold" on Wednesday. The bank also reduced its price target for Novo Nordisk's American depositary...
Novo Nordisk launches Awiqli, first once-weekly US insulin for adult diabetes
Novo Nordisk launched Awiqli in the U.S. as the first once-weekly basal insulin for adults with type 2 diabetes. The new treatment option aims to improve...
🔴 Novo Nordisk is trading 3.02% down in pre-market as no clear company-specific catalyst emerges
Novo Nordisk is trading 3.02% down at $45.75, with no fresh company-specific announcement clearly explaining the August 12 pre-market decline. - It fell from...
🟢 Novo Nordisk is trading 4.4% up today after raising FY26 guidance and beating Q2 revenue expectations
Novo Nordisk is trading 4.4% up at $46.50 in pre-market action, rebounding from recent volatility as investors react to the company raising its full-year 2026...
Novo Nordisk lifts 2026 outlook after strong second quarter with 7% adjusted sales growth at CER.
Novo Nordisk reported second quarter adjusted sales growth of 7% and adjusted operating profit growth of 11%, both at constant exchange rates (CER). Citing...
Novo Nordisk's second quarter revenue beats on GLP-1 strength, but impairments hit EPS; company lifts 2026 guidance.
Novo Nordisk reported second quarter 2026 revenue of DKK 78.5 billion ($12.26 billion), beating estimates, while diluted EPS of DKK 4.75 ($0.74) missed...